Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBIT: 2009-2024

Historic EBIT for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to $24.9 million.

  • Amicus Therapeutics' EBIT rose 58.22% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 529.46%. This contributed to the annual value of $24.9 million for FY2024, which is 132.22% up from last year.
  • Latest data reveals that Amicus Therapeutics reported EBIT of $24.9 million as of FY2024, which was up 132.22% from -$77.2 million recorded in FY2023.
  • Amicus Therapeutics' 5-year EBIT high stood at $24.9 million for FY2024, and its period low was -$247.0 million during FY2020.
  • Moreover, its 3-year median value for EBIT was -$77.2 million (2023), whereas its average is -$88.2 million.
  • As far as peak fluctuations go, Amicus Therapeutics' EBIT fell by 2.75% in 2022, and later surged by 132.22% in 2024.
  • Over the past 5 years, Amicus Therapeutics' EBIT (Yearly) stood at -$247.0 million in 2020, then increased by 16.42% to -$206.4 million in 2021, then declined by 2.75% to -$212.1 million in 2022, then surged by 63.60% to -$77.2 million in 2023, then surged by 132.22% to $24.9 million in 2024.